Why clinical trial, Managed Access and Early Access medicines now need specialist depots in Australia and the Asia Pacific.
Australia and the wider Asia–Pacific region are tightening expectations around how Clinical Trials, Managed Access Program (MAP), Early Access Program (EAP) and post-trial medicines are stored and distributed. Products are more complex and higher value, governance around access programs has matured, and hospitals and sponsors are applying existing wholesaling and cold-chain requirements more rigorously. For CRO project managers and clinical operations teams, this is turning depot choice into a critical study decision rather than a back-office logistics task.
Australia’s Requirements for Safe Clinical Storage
Australian clinical trial guidance requires clearly defined storage temperatures, supported by written procedures for storage, monitoring, accountability, and destruction, with hospital SOPs implementing these requirements through segregated storage, calibrated continuous monitoring, temperature mapping, and documented excursion management. In parallel, Council of Australian Therapeutic Advisory Groups (CATAG) guidance and state medicines governance policies encourage hospitals and sponsors to manage MAP and EAP supply within the same quality and safety framework applied to formulary and trial medicines. Sponsors must be able to produce traceable, audit-ready records for every pack supplied, whether under a trial, an early access arrangement or post-trial treatment.
Why General Warehouses No Longer Meet Clinical Standards
The Australian Code of Good Wholesaling Practice for Medicines in Schedules 2, 3, 4 and 8 has, since 2011, treated third-party logistics and distribution providers as part of the medicines supply chain. What has changed is how hospitals, sponsors and regulators now apply these expectations to clinical, MAP, EAP and post-trial supply. Global GDP principles, experience from large vaccine programs and the focus on high-risk, high-cost medicines mean depots are expected to operate with the same level of control as manufacturers and hospital pharmacies. The requirements for clinical trial, MAP and EAP supply have evolved significantly, and specialist pharmaceutical 3PL/4PL depots with validated, documented infrastructure are now expected for these applications. In this environment, independent, licensed pharmaceutical 3PL and 4PL depots allow sponsors and CROs to separate storage and logistics risk from manufacturing while meeting higher expectations for control and documentation. Centralising Australian stock, accountability and records in a single specialist depot provides a consistent platform across studies and access programs, reducing variation between sites and simplifying responses to audits and inspections.
Integrated Storage, IOR and Distribution for Clinical Supply
HL Pharma operates as an independent, licensed pharmaceutical 3PL and 4PL partner in Melbourne, focused on this specialist role. We provide secure pharmaceutical storage in temperature-mapped controlled room temperature, refrigerated, frozen and ultra-low environments for commercial, clinical, MAP, EAP and post-trial medicines. For international sponsors and CROs, HL Pharma can act as Importer of Record (IOR) into Australia, coordinating regulatory and customs requirements and simplifying inbound clinical, MAP and EAP shipments before they enter storage. This allows Australian clinical trial, Managed Access and Early Access supply to be integrated into global study logistics without adding another layer of local complexity. HL Pharma’s operations are supported by an ISO 9001:2015 certified electronic quality management system with GDP-aligned procedures, structured deviation and corrective and preventive action (CAPA) management, validated cold-chain packaging and specialist healthcare logistics partners for national distribution. A dedicated client portal, linked to our warehouse management system, provides visibility of inventory, batch and expiry data, quarantine status and order progress so study teams can access inspection-ready documentation without chasing multiple providers. For project and operations teams, this offers a single licensed depot and Importer of Record partner for clinical trial, Managed Access, Early Access and post-trial medicines in Australia. This approach supports cleaner accountability, more consistent documentation, and greater operational focus on study delivery and patient access.
HL Pharma delivers specialist pharmaceutical storage and logistics for clinical and access program medicines. Reach out today to see how we can support your project here.